Dopamine Transporter Imaging as Objective Monitoring Biomarker in Parkinson's Disease
Open Access
- 27 March 2025
- journal article
- Published by Wiley in Annals of Neurology
- Vol. 98 (1) , 120-135
Abstract
Objective: Although dopamine transporter (DaT) imaging is a valuable diagnostic biomarker, few studies have investigated its utility in objectively monitoring disease progression in patients with Parkinson's disease (PD). To date, no study has established a longitudinal relationship between the DaT signal decline and the motor symptom increase, potentially due to neglected factors such as brain regions, disease laterality, and symptom subtypes, which this study addresses.Methods: This cohort study included participants who met the Movement Disorder Society (MDS) criteria for PD, with longitudinal imaging and clinical data from the Parkinson's Progression Markers Initiative Database. Linear mixed model analyses were used to investigate the relationship between the DaT signal decline and the motor symptom severity increase over time. We hypothesized that a decline in putaminal DaT availability in the less affected hemisphere would be associated with increasing contralateral motor symptoms, measured by the Unified Parkinson's Disease Rating Scale (UPDRS). Additional models explored the effects of different brain regions (caudate and putamen), symptom categories (MDS UPDRSIII score with and without tremor items), and disease onset laterality (left or right hemisphere).Results: We included 719 participants (443 male patients and 276 female patients; mean age = 62.2 ± 9.5 years) with 1,981 available data points. As hypothesized, we observed a significant association between the decrease in the less affected putaminal DaT signal and motor symptom increase in the contralateral body side, independent of including or excluding tremor scores.Interpretation: Our findings support the use of repetitive DaT imaging for objectively monitoring PD progression. This could facilitate personalized disease tracking, subtyping, and intervention testing in the future. ANN NEUROL 2025;98:120–135Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (DR 445/9‐1, project ID 233886668/RTG 1960, project‐ID 431549029 ‐ C03 ‐ CRC1451)
This publication has 34 references indexed in Scilit:
- The Concept of Motor Reserve in Parkinson's Disease: New Wine in Old Bottles?Movement Disorders, 2022
- Diagnosis and Treatment of Parkinson DiseaseJAMA, 2020
- Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative CohortMovement Disorders, 2018
- Progression of MDS‐UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative CohortMovement Disorders Clinical Practice, 2017
- Ipsilateral deficits of dopaminergic neurotransmission in Parkinson's diseaseAnnals of Clinical and Translational Neurology, 2015
- MDS clinical diagnostic criteria for Parkinson's diseaseMovement Disorders, 2015
- When Does Parkinson Disease Start?Archives of Neurology, 2010
- Correlation of dopamine transporter imaging with parkinsonian motor handicap: How close is it?Movement Disorders, 2003
- Correlation of Parkinson's disease severity and duration with123I-FP-CIT SPECT striatal uptakeMovement Disorders, 2000
- The Nigrostriatal Dopaminergic System Assessed In Vivo by Positron Emission Tomography in Healthy Volunteer Subjects and Patients With Parkinson's DiseaseArchives of Neurology, 1990